Renin-angiotensin system (ACEIs and/or ARBs) (versus unexposed) updated on 03-11-2025

Genital anomalies

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S14211
R55723		 Colvin - ACEi, 2014 Congenital anomalies of genital organs (ICD-9: 752) 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: Yes Indications Antihypertensive: All hypertensions, any indications or not specified Renin angiotensin: ACEIs (Angiotensin-converting enzyme inhibitors) 6.77 [2.70;16.96] -/84   846/97,533 - 84
ref
S13936
R54562		 Vasilakis-Scaramozza - ACE inhibitors, 2013 Genital anomalies 1st trimester retrospective cohort unexposed (general population or NOS) Adjustment: Yes Indications Antihypertensive: All hypertensions, any indications or not specified Renin angiotensin: ACEIs (Angiotensin-converting enzyme inhibitors) 3.80 [0.90;16.00] 1/46   4/682 5 46
ref
Total 2 studies 5.73 [2.64;12.42] 5 130
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Colvin - ACEi, 2014Colvin - ACEi, 2014 6.77[2.70; 16.96]-8471%ROB confusion: seriousROB selection: moderateROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: critical Vasilakis-Scaramozza - ACE inhibitors, 2013Vasilakis-Scaramozza - ACE inhibitors, 2013 3.80[0.90; 16.00]54629%ROB confusion: seriousROB selection: moderateROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 0% 5.73[2.64; 12.42]51300.920.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 5.73[2.64; 12.42]51300%NAColvin - ACEi, 2014 Vasilakis-Scaramozza - ACE inhibitors, 2013 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 5.73[2.64; 12.42]51300%NAColvin - ACEi, 2014 Vasilakis-Scaramozza - ACE inhibitors, 2013 2 Tags Adjustment   - Yes  - Yes 5.73[2.64; 12.42]51300%NAColvin - ACEi, 2014 Vasilakis-Scaramozza - ACE inhibitors, 2013 2 Indications Antihypertensive   - All hypertensions, any indications ...  - All hypertensions, any indications or not specified 5.73[2.64; 12.42]51300%NAColvin - ACEi, 2014 Vasilakis-Scaramozza - ACE inhibitors, 2013 2 Renin angiotensin   - ACEIs (Angiotensin-converting enzym ...  - ACEIs (Angiotensin-converting enzyme inhibitors) 5.73[2.64; 12.42]51300%NAColvin - ACEi, 2014 Vasilakis-Scaramozza - ACE inhibitors, 2013 2 All studiesAll studies 5.73[2.64; 12.42]51300%NAColvin - ACEi, 2014 Vasilakis-Scaramozza - ACE inhibitors, 2013 20.520.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 5.73[2.64; 12.42]8421300%NAColvin - ACEi, 2014 Vasilakis-Scaramozza - ACE inhibitors, 2013 20.510.01.0